Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 23, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the RBC Capital Markets Global Healthcare Conference at 8:00 AM EST on Wednesday,...
-
Feb 19, 2016DUBLIN HEADQUARTERS CENTRAL TO EUROPEAN & GLOBAL GROWTH STRATEGY
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), announced that a number of key public facing corporate functions will be relocated to Ireland as part of the Company's focused international...
-
Feb 18, 2016- Delivered record calendar year 2015 net sales of $5.35 billion, an increase of 28% compared to the prior year; with adjusted net income of $1.09 billion, an increase of 29% compared to the prior year; and adjusted earnings per share of $7.59, an increase of 21% compared to the prior year
Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the fourth quarter and calendar year ended December 31, 2015. Perrigo's Chairman and CEO Joseph C. Papa commented, "The team...
-
Feb 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on March 15, 2016 to shareholders of record on...
-
Feb 11, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will announce financial results for its calendar year and fourth quarter 2015 on Thursday, February 18, 2016 at approximately 6:00...
-
Jan 25, 2016- Acquires high barrier-to-entry assets that fit well within Perrigo's unique Rx extended topicals portfolio
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A®...
-
Jan 11, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced today that, following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall in the US to the retail...
-
Jan 11, 2016- Expects full-year 2016 adjusted earnings per diluted share to be in a range of $9.50 to $10.10, an increase of 24% to 29% over 2015 adjusted earnings per diluted share guidance range of $7.65 to $7.85
Perrigo Company plc (NYSE: PRGO; TASE) today increased full-year 2016 adjusted earnings per diluted share guidance to be in a range of $9.50 to $10.10, up from the Company's October 22, 2015...
-
Jan 4, 2016
Allergan plc (NYSE: AGN) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced the launch of combination guaifenesin 600mg and pseudoephedrine HCl 60mg extended-release tablets to...
-
Dec 29, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph Papa will present at the 34th Annual J.P. Morgan Healthcare Conference at 8:00 AM PST on Monday, January...